Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism
Gemma Brufau, Frans Stellaard, Kris Prado, Vincent W. Bloks, Elles Jonkers, Renze Boverhof, Folkert Kuipers, Elizabeth J. Murphy – 19 August 2010 – Bile acids (BAs) are essential for fat absorption and appear to modulate glucose and energy metabolism. Colesevelam, a BA sequestrant, improves glycemic control in type 2 diabetes mellitus (T2DM). We aimed to characterize the alterations in BA metabolism associated with T2DM and colesevelam treatment and to establish whether metabolic consequences of T2DM and colesevelam are related to changes in BA metabolism.